+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Alpha Synuclein"

Alpha-synuclein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-synuclein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Multiple System Atrophy - Pipeline Insight, 2024 - Product Thumbnail Image

Multiple System Atrophy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 75 Pages
  • Global
From
From
Parkinson's Disease - Epidemiology Forecast - 2032 - Product Thumbnail Image

Parkinson's Disease - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 142 Pages
  • Global
From
From
From
From
Disease Analysis: Parkinson's Disease - Product Thumbnail Image

Disease Analysis: Parkinson's Disease

  • Report
  • March 2021
  • 75 Pages
  • Global
Alpha Synuclein - Pipeline Review, H1 2020 - Product Thumbnail Image

Alpha Synuclein - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 150 Pages
  • Global
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Alpha Synuclein is a protein found in the brain and other parts of the nervous system. It is involved in the regulation of neurotransmitter release and is believed to play a role in the development of Parkinson's disease. As such, it has become an important target for drug development in the Central Nervous System (CNS) drugs market. Alpha Synuclein-targeting drugs are being developed to treat Parkinson's disease, as well as other neurological disorders such as dementia and multiple system atrophy. These drugs are designed to reduce the amount of Alpha Synuclein in the brain, which is believed to be a major contributor to the progression of these diseases. In addition to drug development, research is also being conducted into the role of Alpha Synuclein in other neurological disorders, such as Alzheimer's disease and amyotrophic lateral sclerosis. This research is aimed at understanding the role of Alpha Synuclein in the development of these diseases, and developing treatments that target the protein. Companies in the Alpha Synuclein market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more